| Drug General Information |
| Drug ID |
D0NR6T
|
| Former ID |
DNCL001948
|
| Drug Name |
UB-311
|
| Indication |
Alzheimer disease [ICD9: 331; ICD10:G30]
|
Phase 2 |
[1]
|
|---|
| Company |
United Biomedical
|
| Target and Pathway |
| Target(s) |
Amyloid beta A4 protein |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Notch signaling pathway
|
|
Alzheimer's disease
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Degradation of the extracellular matrix
|
|
Regulated proteolysis of p75NTR
|
|
NRIF signals cell death from the nucleus
|
|
Activated NOTCH1 Transmits Signal to the Nucleus
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Signaling by ERBB4
|
|
Signaling by NOTCH3
|
|
Signaling by NOTCH4
|
|
Signaling by NOTCH1
|
|
Signaling by NOTCH2
|
|
Notch Signaling Pathway
|
|
Alzheimers Disease
|
|
Signalling by NGF
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02551809) Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients. |
|---|
| REF 2 | Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7. |
|---|
